0.900
0.02 (2.44%)
| Previous Close | 0.878 |
| Open | 0.873 |
| Volume | 675,840 |
| Avg. Volume (3M) | 1,938,126 |
| Market Cap | 75,989,920 |
| Price / Sales | 1.12 |
| Price / Book | 1.70 |
| 52 Weeks Range | |
| Earnings Date | 11 Aug 2025 - 15 Aug 2025 |
| Operating Margin (TTM) | -440.66% |
| Diluted EPS (TTM) | -2.96 |
| Quarterly Revenue Growth (YOY) | -87.00% |
| Total Debt/Equity (MRQ) | 51.91% |
| Current Ratio (MRQ) | 2.60 |
| Operating Cash Flow (TTM) | -191.54 M |
| Levered Free Cash Flow (TTM) | -79.80 M |
| Return on Assets (TTM) | -34.74% |
| Return on Equity (TTM) | -234.19% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bearish |
| Biotechnology (Global) | Mixed | Bearish | |
| Stock | Sutro Biopharma, Inc. | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | -1.5 |
| Insider Activity | -3.0 |
| Price Volatility | 0.5 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 0.5 |
| Average | -0.20 |
|
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 4.11% |
| % Held by Institutions | 79.73% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Merck & Co., Inc. | 31 Mar 2025 | 2,723,509 |
| Vestal Point Capital, Lp | 31 Mar 2025 | 2,600,000 |
| Adage Capital Partners Gp, L.L.C. | 31 Mar 2025 | 2,000,000 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 2.00 (Wedbush, 122.30%) | Hold |
| 2.00 (HC Wainwright & Co., 122.30%) | Hold | |
| Median | 2.00 (122.30%) | |
| Low | 0.800 (B of A Securities, -11.08%) | Sell |
| Average | 1.60 (77.84%) | |
| Total | 2 Hold, 1 Sell | |
| Avg. Price @ Call | 0.853 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| B of A Securities | 19 May 2025 | 0.800 (-11.08%) | Sell | 0.880 |
| 14 Mar 2025 | 1.00 (11.15%) | Sell | 0.810 | |
| HC Wainwright & Co. | 29 Apr 2025 | 2.00 (122.30%) | Hold | 0.870 |
| 17 Mar 2025 | 2.00 (122.30%) | Hold | 0.930 | |
| Wedbush | 14 Mar 2025 | 2.00 (122.30%) | Hold | 0.810 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| ALBINI EDWARD C | - | 0.880 | -15,995 | -14,076 |
| Aggregate Net Quantity | -15,995 | |||
| Aggregate Net Value ($) | -14,076 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 0.880 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| ALBINI EDWARD C | Officer | 15 May 2025 | Disposed (-) | 15,995 | 0.880 | 14,076 |
| ALBINI EDWARD C | Officer | 15 May 2025 | Option execute | 44,719 | - | - |
| Date | Type | Details |
|---|---|---|
| 08 May 2025 | Announcement | Sutro Biopharma Reports First Quarter 2025 Financial Results and Business Highlights |
| 01 May 2025 | Announcement | Sutro Biopharma to Participate in Upcoming Investor Conferences |
| 28 Apr 2025 | Announcement | Sutro Biopharma to Highlight its Next-Generation Exatecan and Dual-Payload ADC Programs in Presentations at AACR 2025 |
| 15 Mar 2025 | Announcement | Sutro Biopharma Presents Data from Dose-Optimization Portion of REFRαME-O1 Trial in Patients with Platinum Resistant Ovarian Cancer at SGO 2025 |
| 13 Mar 2025 | Announcement | Sutro Biopharma Reports Full Year 2024 Financial Results and Business Highlights |
| 13 Mar 2025 | Announcement | Sutro Biopharma Announces Strategic Portfolio Review Resulting in the Prioritization of its Next-Generation ADC Pipeline |
| 03 Mar 2025 | Announcement | Sutro Biopharma to Present at the TD Cowen 45th Annual Health Care Conference |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |